Episodic Migraine

In three clinical trials, treatment with atogepant relieved migraine symptoms as soon as day 1, with consistent reductions through 4 weeks compared with placebo, according to research published in Neurology.

Ajovy offers “significant efficacy” compared with placebo to address episodic migraine in children and adolescents, according to topline results from the phase 3 SPACE study.

SAN DIEGO — Distinctions between burdens faced by those who experience different levels of chronic and episodic migraine should be drawn according to external health care-related factors rather than by symptoms alone, according to a poster.

SAN DIEGO —Individuals with episodic migraine had lower nutrient intake on days with nausea or vomiting compared with days without nausea, according to a poster from the American Headache Society Annual Scientific Meeting.

SAN DIEGO — Concurrent use of atogepant for preventive treatment of episodic migraine and ubrogepant for acute migraine treatment was safe and well-tolerated at 12 weeks, according to a study.

BOSTON – Treatment with once-daily atogepant significantly reduced monthly migraine days in adults with episodic migraine compared with placebo, according to preliminary data presented at the American Academy of Neurology annual meeting.

Oral Nurtec ODT 75 mg taken every other day effectively prevented migraines, according to results of a randomized, double-blind, placebo-controlled trial presented at the American Headache Society Virtual Annual Scientific Meeting.

Aimovig monotherapy demonstrated sustained efficacy up to 64 weeks among patients with episodic migraine who were unsuccessfully treated with multiple other preventive therapies, according to study findings published in Neurology.

The FDA has expanded the approval of a remote electrical neuromodulation device to treat episodic and chronic migraine in children aged 12 years and older, according to a press release issued by the manufacturer.

In the phase 3 MOMENTUM and INTERCEPT trials, the investigational migraine drug AXS-07 met its coprimary endpoints of pain freedom and freedom from most bothersome symptom at 2 hours compared with placebo.